Contact
Please use this form to send email to PR contact of this press release:
Oxidien Pharmaceuticals Announces Favorable Response from FDA on Proposed Development Plan
TO:
Helena Cowley
Oxidien Pharmaceuticals, LLC
+1 352-672-5320